Visibility evaluation of gastric epithelial neoplasm of fundic gland mucosa lineage using texture and color enhancement imaging

利用纹理和颜色增强成像技术评估胃底腺黏膜来源的胃上皮肿瘤的可见性

阅读:1

Abstract

OBJECTIVES: Recently, the incidence of Helicobacter pylori-uninfected gastric cancers, such as gastric epithelial neoplasm of fundic-gland mucosa lineage (GEN-FGML), has increased with the widespread use of eradication therapy. Because the detection and endoscopic diagnosis of GEN-FGML are difficult, an effective observation method in screening endoscopy is required. We investigated whether texture and color enhancement imaging (TXI) improved the visibility of GEN-FGML compared with white light imaging (WLI). METHODS: In this single-center prospective clinical study, 50 GEN-FGML lesions (35 patients) treated at our hospital between October 2020 and June 2023 were analyzed. The endoscopic images of GEN-FGML obtained using WLI, TXI mode 1 (TXI-1), TXI mode 2 (TXI-2), and narrow-band imaging were compared by 10 endoscopists. We analyzed the visibility score and inter-rater reliability (intraclass correlation coefficient and conducted an objective evaluation based on L* a* b* color values and the color difference (ΔE*) in the CIE LAB color space system. RESULTS: Histologically, GEN-FGML was classified as gastric adenocarcinoma of fundic-gland type (n = 45) and gastric adenocarcinoma of fundic-gland mucosa type (n = 5). The total visibility score for all endoscopists was significantly higher for TXI than for WLI (p < 0.01); and for TXI-1 than for TXI-2 (p < 0.01). The intraclass correlation coefficients for TXI-1 and TXI-2 were "almost perfect" and "substantial," respectively, for all endoscopists. ΔE* was significantly higher for TXI than for WLI (p < 0.01). CONCLUSIONS: TXI improved the visibility of GEN-FGML for all endoscopists compared with WLI when evaluated subjectively and objectively.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。